HCK: A Drug Target / Disease Biomarker (G3055)

Target Name: HCK

NCBI ID: G3055

HCK: A Drug Target / Disease Biomarker

HCK, also known as protamineuron, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a key regulator of the growth and development of tissues and is involved in the formation of new blood vessels, as well as the regulation of cell death and survival.

Recent studies have suggested that HCK may have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because HCK has been shown to play a role in the development and progression of these conditions, and may be able to serve as a diagnostic or therapeutic target.

One of the key reasons for the potential of HCK as a drug target is its involvement in the regulation of cell survival. Studies have shown that HCK plays a role in the regulation of cell survival by promoting the production of pro-survival molecules, such as p53, and by inhibiting the production of pro-apoptotic molecules, such as caspase-3. This suggests that HCK may be a useful target for drugs that are designed to promote cell survival or prevent cell death.

Another potential drug target for HCK is its role in the regulation of blood vessel formation. Studies have shown that HCK is involved in the regulation of blood vessel formation by promoting the production of blood vessels and by inhibiting the production of factors that are involved in blood vessel rejection. This suggests that HCK may be a useful target for drugs that are designed to promote blood vessel formation or prevent blood vessel rejection.

In addition to its potential as a drug target, HCK has also been suggested as a potential biomarker for various diseases. Studies have shown that HCK is often elevated in the blood of people with cancer, and that it may be a useful biomarker for monitoring the effectiveness of cancer treatments. This is because HCK is often reduced in the blood of people with cancer, and may serve as a reliable indicator of the effectiveness of these treatments.

Another potential use for HCK as a biomarker is its role in the regulation of cell death. Studies have shown that HCK plays a role in the regulation of cell death by promoting the production of pro-survival molecules and by inhibiting the production of pro-apoptotic molecules. This suggests that HCK may be a useful biomarker for monitoring the severity of tissue damage or injury.

In conclusion, HCK has shown potential as a drug target and biomarker for various diseases. Its involvement in the regulation of cell survival and blood vessel formation, as well as its potential as a reliable indicator of the effectiveness of cancer treatments, make it an attractive target for further research and development.

Protein Name: HCK Proto-oncogene, Src Family Tyrosine Kinase

Functions: Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS

More Common Targets